CLAIMS

1. An antibody, which has a human FcRn-binding activity at an acidic and neutral pH, and a lower antigen-binding activity at the acidic pH than at the neutral pH, wherein the acidic pH is 5.8 and the neutral pH is 7.4, wherein the human FcRn-binding activity at the neutral pH is stronger than that of a human IgG1 comprising an unmodified Fc region, wherein the human FcRn-binding activity at pH 7.0 and 25°C is stronger than KD 3.2 micromolar, wherein the ratio of antigen-binding activity at the acidic pH and neutral pH is at least 2 in the value of KD (at the acidic pH)/KD (at the neutral pH), wherein the antibody comprises an amino acid mutation of the antigen-binding domain, which comprises a substitution of histidine for at least one amino acid of the antigen-binding domain or the insertion of at least one histidine, wherein the antibody comprises as the human FcRn-binding domain an Fc domain resulting from substituting a different amino acid for at least one amino acid in the Fc domain of a human IgG1, IgG2, IgG3, or IgG4, wherein the human FcRn-binding domain is a human FcRn-binding domain comprising an amino acid sequence with a substitution of a different amino acid for at least one amino acid selected from those of positions 237, 238, 239, 248, 250, 252, 254, 255, 256, 257, 258, 265, 270, 286, 289, 297, 298, 303, 305, 307, 308, 309, 311, 312, 314, 315, 317, 325, 332, 334, 360, 376, 380, 382, 384, 385, 386, 387, 389, 424, 428, 433, 434, and 436 (EU numbering) in the Fc domain of a human IgG1, IgG2, IgG3, or IgG4, wherein the antibody has the augmented ability of an antibody to eliminate an antigen from plasma.

2. The antibody of claim 1, which comprises a human FcRn-binding domain comprising amino acid substitution in the Fc domain of the human IgG1, IgG2, IgG3, or IgG4 which comprises at least one amino acid substitution selected from:
an amino acid substitution of Met for Gly at position 237;
an amino acid substitution of Ala for Pro at position 238;
an amino acid substitution of Lys for Ser at position 239;
an amino acid substitution of Ile for Lys at position 248;
an amino acid substitution of Ala, Phe, Ile, Met, Gln, Ser, Val, Trp, or Tyr for Thr at position 250;
an amino acid substitution of Phe, Trp, or Tyr for Met at position 252;
an amino acid substitution of Thr for Ser at position 254;
an amino acid substitution of Glu for Arg at position 255;
an amino acid substitution of Asp, Glu, or Gln for Thr at position 256;
an amino acid substitution of Ala, Gly, Ile, Leu, Met, Asn, Ser, Thr, or Val for Pro at position 257;
an amino acid substitution of His for Glu at position 258;